ENDPOINTS

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

One of the last big pharma holdouts in obesity has now entered what has become the most sought-after field in the industry. AbbVie said Monday morning it's making the leap into the obesity field for ...

Mar 3, 2025 - 09:57
 0
AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin
One of the last big pharma holdouts in obesity has now entered what has become the most sought-after field in the industry. AbbVie said Monday morning it's making the leap into the obesity field for ...
Read More

Tags:

Previous Article

Two patients navigate the new Alzheimer's drugs

Next Article

Emissions in trade: Where are they and how do we measure them?

Related Posts

Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more

Q4 earnings updates; Biogen details revised research st...

Feb 9, 2025  0

Ascletis’ obesity pill looks similar to Roche’s drug, early data suggest

Ascletis’ obesity pill looks similar to Roche’s drug, e...

Feb 19, 2025  0

Exclusive: CRISPR delivery startup Spotlight Therapeutics shuts down

Exclusive: CRISPR delivery startup Spotlight Therapeuti...

Feb 19, 2025  0